CAS NO: | 143-67-9 |
生物活性 | Vinblastine sulfate is a cytotoxic alkaloid used against variouscancertypes. Vinblastine sulfate inhibits the formation of microtubule and suppressesnAChRwith anIC50of 8.9 μM. | ||||||||||||||||
IC50& Target | IC50: 8.9 μM(nAChR)[1] | ||||||||||||||||
体外研究 (In Vitro) | Vinblastine does not depolymerize spindle microtubules, yet it powerfully blocks mitosis (for example, IC500.8 nM in HeLa cells) and cells die by apoptosis[2]. In NB4 cells, vinblastine produces alteration of p53 and DNA fragmentation. Vinblastine treatment has an antiproliferative effect via the induction of apoptosis producing Bax/Bcl-2 imbalance. Vinblastine treatment suppresses NFκB expression and depresses NFκB-DNA binding activity while maintaining JNK activation that subsequently results in apoptotic response through caspase-dependent pathway[3]. Vinblastine is found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase[4]. | ||||||||||||||||
体内研究 (In Vivo) | Vinblastine is a widely used anticancer drug with undesired side effects. Its conjugation with carrier molecules could be an efficient strategy to reduce these side effects[5]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 909.05 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C46H60N4O13S | ||||||||||||||||
CAS 号 | 143-67-9 | ||||||||||||||||
中文名称 | 硫酸长春碱 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 50 mg/mL(55.00 mM;Need ultrasonic) DMSO : ≥ 44 mg/mL(48.40 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |